NAUT (41) QTRX (28) SEER (30) CTKB (41) ⌘ Pro Terminal →

Standard BioTools Inc. (LAB) — RQD Stock Rating Cockpit

$0.62 +0.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Standard BioTools Inc. (LAB) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $244.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LAB)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

37.830 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE3% OF RANGE

L: $1$0.62H: $2

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 3 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on LAB

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (15)

-28.7% ROIC with 49.9% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 0.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (55)

20/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like LAB

✓Big institutional funds and options desks are actively positioning on the bullish side.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LAB)

✓Walkthrough of LAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.33%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.62H $0.62L $0.60C $0.62VOL 1.00M

RES: $0.75SUP: $0.59SMA50: $0.68SMA200: $0.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LAB Butterfly Map → + Track LAB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -6.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LAB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LAB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LAB)

Health Care Rank #612 of 1016 ⚔️ NAUT vs LAB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LAB vs. NAUT, QTRX, SEER, CTKB)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Standard BioTools Inc. (LAB) ranks #612 by composite RQD confidence (41/100, grade D-) and #553 by equity capitalization ($244.7M). Within this direct 5-issuer industry benchmark cohort, LAB leads on earnings valuation at N/A trailing P/E, while CTKB leads on capital efficiency and profitability with -12.7% ROIC and 51.8% gross margin. LAB currently leads its immediate peer cohort in composite quantitative strength at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LAB ACTIVE Standard BioTools Inc.	D-	41/100	—	49.9%	-28.7%	+0.49%	$244.7M	Benchmark Subject
NAUT Nautilus Biotechnology Inc.	D-	41/100	—	—	-35.0%	-2.18%	$399.9M	/naut-vs-lab →
QTRX Quanterix Corporation	E	28/100	—	46.8%	-35.0%	+0.80%	$148.7M	/qtrx-vs-lab →
SEER Seer Inc. (Class A)	E	30/100	—	51.1%	-29.1%	-2.51%	$107.4M	/seer-vs-lab →
CTKB Cytek Biosciences Inc.	D-	41/100	—	51.8%	-12.7%	+2.61%	$818.9M	/ctkb-vs-lab →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001162194

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Standard BioTools Inc. (LAB) reported GAAP revenue of $85.3M (-6.2% vs. FY2024 revenue of $91.0M , and -19.8% cumulative change since FY2023) , GAAP net income of -$74.9M, operating cash flow of -$74.3M, and free cash flow of -$82.6M (+45.6% YoY). On the balance sheet, LAB closed FY2025 with $567.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$85.3M	-$74.9M	-$74.3M	-$82.6M	$567.8M	—
FY2024 (FY)	2024-12-31	$91.0M	-$138.9M	-$143.5M	-$151.8M	$612.3M	—
FY2023 (FY)	2023-12-31	$106.3M	-$74.7M	-$43.3M	-$43.3M	—	—

3. LAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Standard BioTools Inc. (NASDAQ: LAB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.62 (+0.49% 1D, market cap $244.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LAB ranks #612 in composite RQD confidence.

How does LAB compare to NAUT and QTRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), LAB carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 49.9%, and ROIC of -28.7%. By comparison, NAUT (Nautilus Biotechnology Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $399.9M) and QTRX (Quanterix Corporation) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $148.7M). Among the 5-stock peer group, LAB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LAB?

Per LAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001162194), Standard BioTools Inc. generated $85.3M in revenue (-6.2% YoY), -$74.9M in net income, and -$82.6M in free cash flow against $567.8M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LAB trading relative to its 50-day, 200-day, and 52-week technical levels?

LAB last traded at $0.62 (+0.49% on volume of 445,806 shares), positioning the stock -8.82% below its 50-day simple moving average ($0.68) and -32.61% below its 200-day simple moving average ($0.92). Across its 52-week range of $0.59 to $1.72, LAB sits at the 2.7% percentile with a 14-day RSI of 37.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.70).

LAB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell LAB stock right now?

Standard BioTools Inc. (LAB) currently earns a Roarable Rating of D- (Sell — SELL) with 41/100 RQD Confidence. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.

What is LAB's 12-month price target and RQD AI Jury consensus?

LAB's 12-month base price target is $0.57 (range $0.44 to $1.81), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: LAB RQD Cockpit LAB 12M Forecast LAB Earnings & Move LAB Dividends & DRIP LAB Insiders & 13F LAB Whale Options LAB Profit Sankey LAB News & Why